| 2003 | A Case of Paraneoplastic Nephrotic Syndrome in a Patient with Ovarian Carcinoma
| YONSEI MEDICAL JOURNAL |
| 1997 | A Comparative Study of Intravenous Granisetron Versus Intravenous and Oral Ondansetron in the Prevention of Nausea and Vomiting Associated with Moderately Emetogenic Chemotherapy | American Journal of Clinical Oncology |
| 2010 | A comparative study of protein expression in primary colorectal cancer and synchronous hepatic metastases: the significance of matrix metalloproteinase-1 expression as a predictor of liver metastasis | SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY |
| 2007 | A comparative study of volumetric analysis, histopathologic downstaging, and tumor regression grade in evaluating tumor response in locally advanced rectal cancer following preoperative chemoradiation | INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS |
| 2012 | A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets.
| GUT |
| 2011 | A densely interconnected genome-wide network of microRNAs and oncogenic pathways revealed using gene expression signatures
| PLOS GENETICS |
| 2017 | A First-Time-in-Human Study of GSK2636771, a Phosphoinositide 3 Kinase Beta-Selective Inhibitor, in Patients with Advanced Solid Tumors | CLINICAL CANCER RESEARCH |
| 2007 | A Locally Advanced Breast Cancer with Difficult Differential Diagnosis of Carcinosarcoma and Atypical Medullary Carcinoma, which had Poor Response to Adriamycin- and ...
| CANCER RESEARCH AND TREATMENT |
| 2009 | A multi-center phase II study of S-1 plus paclitaxel as first-line therapy for patients with advanced or recurrent unresectable gastric cancer | CANCER CHEMOTHERAPY AND PHARMACOLOGY |
| 2019 | A Multicenter Phase II Study of AMG 337 in Patients with MET-Amplified Gastric/Gastroesophageal Junction/Esophageal Adenocarcinoma and Other MET-Amplified Solid Tumors | Clinical Cancer Research |
| 2017 | A non-randomized, open-label, single-arm, Phase 2 study of emibetuzumab in Asian patients with MET diagnostic positive, advanced gastric cancer
| CANCER CHEMOTHERAPY AND PHARMACOLOGY |
| 2016 | A novel TP53-KPNA3 translocation defines a de novo treatment-resistant clone in osteosarcoma
| COLD SPRING HARBOR MOLECULAR CASE STUDIES |
| 2017 | A phase 1, open label, dose escalation study to investigate the safety, tolerability, and pharmacokinetics of MG1102 (apolipoprotein(a) Kringle V) in patients with solid tumors | INVESTIGATIONAL NEW DRUGS |
| 2020 | A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data
| GASTRIC CANCER |
| 2010 | A phase I pharmacokinetic and pharmacodynamic study of CKD-732, an antiangiogenic agent, in patients with refractory solid cancer | INVESTIGATIONAL NEW DRUGS |
| 2012 | A phase I pharmacokinetic study of TSU-68 (a multiple tyrosine kinase inhibitor of VEGFR-2, FGF and PDFG) in combination with S-1 and oxaliplatin in metastatic colorectal cancer patients previously treated with chemotherapy. | INVESTIGATIONAL NEW DRUGS |
| 2010 | A phase I/II and pharmacogenomic study of pemetrexed and cisplatin in patients with unresectable, advanced gastric carcinoma. | ANTI-CANCER DRUGS |
| 2012 | A Phase Ib pharmacokinetic study of the anti-angiogenic agent CKD-732 used in combination with capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer patients who progressed on irinotecan-based chemotherapy. | INVESTIGATIONAL NEW DRUGS |
| 2009 | A phase II feasibility study of weekly paclitaxel in heavily pretreated advanced gastric cancer patients with poor performance status | ONCOLOGY |
| 2014 | A phase II open-label randomized multicenter trial of TSU-68 in combination with S-1 and oxaliplatin versus S-1 in combination with oxaliplatin in patients with metastatic colorectal cancer | INVESTIGATIONAL NEW DRUGS |
| 2010 | A phase II study of a combined biweekly irinotecan and monthly cisplatin treatment for metastatic or recurrent gastric cancer. | AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS |
| 2002 | A phase II study of gemcitiabine monotherapy in breast cancer patients refractory to anthracycline and taxane
| CANCER RESEARCH AND TREATMENT |
| 2001 | A Phase II Study of Genexol® ( paclitaxel ) in Metastatic Breast Cancer
| CANCER RESEARCH AND TREATMENT |
| 2006 | A Phase II Study of Infusional 5-Fluorouracil and Low-Dose Leucovorin with Docetaxel for Advanced Gastric Cancer | ONCOLOGY |
| 2008 | A phase II study of paclitaxel combined with infusional 5-fluorouracil and low-dose leucovorin for advanced gastric cancer. | CANCER CHEMOTHERAPY AND PHARMACOLOGY |
| 2007 | A phase II study of S-1 monotherapy administered for 2 weeks of a 3-week cycle in advanced gastric cancer patients with poor performance status
| BRITISH JOURNAL OF CANCER |
| 2004 | A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer
| ANNALS OF ONCOLOGY |
| 2023 | A Phase II Trial of S-1 and Oxaliplatin in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane (KCSG-BR07-03)
| CANCER RESEARCH AND TREATMENT |
| 2006 | A phase II trial of S-1 monotherapy in metastatic colorectal cancer after failure of irinotecan- and oxaliplatin-containing regimens
| BRITISH JOURNAL OF CANCER |
| 2007 | A phase II trial of weekly fractionated irinotecan and cisplatin for advanced gastric cancer | CANCER CHEMOTHERAPY AND PHARMACOLOGY |
| 2012 | A pilot study of S-1 plus cisplatin versus 5-fluorouracil plus cisplatin for postoperative chemotherapy in histological stage IIIB-IV (M0) gastric cancer | INVESTIGATIONAL NEW DRUGS |
| 2005 | A Pilot Study of Trans-Arterial Injection of 166Holmium-Chitosan Complex for Treatment of Small Hepatocellular Carcinoma
| YONSEI MEDICAL JOURNAL |
| 2018 | A Prediction Model of Tumor Progression and Survival in HER2-Positive Metastatic Gastric Cancer Patients Treated with Trastuzumab and Chemotherapy | AAPS JOURNAL |
| 2011 | A prognostic model to predict clinical outcome in gastric cancer patients with bone metastasis | ONCOLOGY |
| 2011 | A randomized phase 2 study of docetaxel and S-1 versus docetaxel and cisplatin in advanced gastric cancer with an evaluation of SPARC expression for personalized therapy
| CANCER |
| 2012 | A randomized phase II trial of S-1-oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer. | EUROPEAN JOURNAL OF CANCER |
| 2022 | A single arm phase Ib/II trial of first-line pembrolizumab, trastuzumab and chemotherapy for advanced HER2-positive gastric cancer
| NATURE COMMUNICATIONS |
| 2009 | A weighted sample size for microarray datasets that considers the variability of variance and multiplicity. | JOURNAL OF BIOSCIENCE AND BIOENGINEERING |
| 2017 | ABCB1 2677G>T/A variant enhances chemosensitivity to anti-cancer agents acting on microtubule dynamics through LAMP1 inhibition | BIOCHEMICAL PHARMACOLOGY |
| 2006 | Activation of Hypoxia-Inducible Factor-1α Is Necessary for Lysophosphatidic Acid–Induced Vascular Endothelial Growth Factor Expression
| CLINICAL CANCER RESEARCH |
| 2009 | Activity of ixabepilone in oestrogen receptor-negative and oestrogen receptor-progesterone receptor-human epidermal growth factor receptor 2-negative metastatic breast cancer | EUROPEAN JOURNAL OF CANCER |
| 2014 | Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: a randomized study (START)
| JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY |
| 2004 | Adeno-associated virus mediated endostatin gene therapy in combination with topoisomerase inhibitor effectively controls liver tumor in mouse model
| WORLD JOURNAL OF GASTROENTEROLOGY |
| 2001 | Adjuvant 5-fluorouracil plus doxorubicin in D2-3 resected gastric carcinoma: 15-year experience at a single institute. | CANCER |
| 2012 | Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. | LANCET |
| 2014 | Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. | LANCET ONCOLOGY |
| 2011 | Advanced detection of recent changing trends in gastric cancer survival: up-to-date comparison by period analysis.
| JAPANESE JOURNAL OF CLINICAL ONCOLOGY |
| 2018 | Alpha-fetoprotein kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo: An analysis of the phase 3 REACH study | BRITISH JOURNAL OF CANCER |
| 1998 | Alpha-fetoprotein-producing gastric cancer | ONCOLOGY REPORTS |
| 2006 | Alteration of hTERT full-length variant expression level showed different gene expression profiles and genomic copy number changes in breast cancer | ONCOLOGY REPORTS |
| 2012 | AMPKα modulation in cancer progression: multilayer integrative analysis of the whole transcriptome in Asian gastric cancer.
| CANCER RESEARCH |
| 2007 | An association between RRM1 haplotype and gemcitabine-induced neutropenia in breast cancer patients
| ONCOLOGIST |
| 2007 | An Attempt for Combining Microarray Data Sets by Adjusting Gene Expressions
| CANCER RESEARCH AND TREATMENT |
| 1998 | An unusual case of gastric carcinoma with synchronous non-Hodgkin's lymphoma
| YONSEI MEDICAL JOURNAL |
| 2010 | Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes | BREAST CANCER RESEARCH AND TREATMENT |
| 2021 | Analysis of the pan-Asian subgroup of patients in the NALA Trial: a randomized phase III NALA Trial comparing neratinib plus capecitabine (N plus C) vs lapatinib plus capecitabine (L plus C) in patients with HER2+metastatic breast cancer (mBC) previously treated with two or more HER2-directed regimens | BREAST CANCER RESEARCH AND TREATMENT |
| 2022 | Analytical and Clinical Validation of Cell-Free Circulating Tumor DNA Assay for the Estimation of Tumor Mutational Burden | CLINICAL CHEMISTRY |
| 2014 | Angiogenic factor thymidine phosphorylase associates with angiogenesis and lymphangiogenesis in the intestinal-type gastric cancer | PATHOLOGY |
| 2008 | Angiogenic factor thymidine phosphorylase increases cancer cell invasion activity in patients with gastric adenocarcinoma.
| MOLECULAR CANCER RESEARCH |
| 2007 | Anti-tumor activity of N-hydroxy-7-(2-naphthylthio) heptanomide, a novel histone deacetylase inhibitor | BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS |
